Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2004 1
2005 1
2006 2
2007 1
2008 2
2009 3
2010 2
2011 2
2012 6
2013 12
2014 11
2015 9
2016 8
2017 1
2018 5
2019 3
2020 3
2021 3
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Among authors: loidl w. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Free article. Clinical Trial.
[Immunotherapy].
Grimm MO, Loidl W. Grimm MO, et al. Among authors: loidl w. Urologe A. 2018 Nov;57(11):1299-1300. doi: 10.1007/s00120-018-0796-y. Urologe A. 2018. PMID: 30406452 German. No abstract available.
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Among authors: loidl w. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, Bauernhofer T, Luger F, Höfner T, Loidl W, Griessner H, Lusuardi L, Bergmaier A, Berger A, Winder T, Weiss S, Bauinger S, Krause S, Drerup M, Heinrich E, Schneider M, Madersbacher S, Vallet S, Stoiber F, Laimer S, Hruby S, Schachtner G, Nagele U, Lenart S, Ponholzer A, Pfuner J, Wiesinger C, Kamhuber C, Müldür E, Bektic J, Horninger W, Heidegger I. Kafka M, et al. Among authors: loidl w. Clin Genitourin Cancer. 2024 Apr;22(2):458-466.e1. doi: 10.1016/j.clgc.2023.12.018. Epub 2024 Jan 4. Clin Genitourin Cancer. 2024. PMID: 38267304 Free article.
Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.
Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M. Vali R, et al. Among authors: loidl w. Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):96-108. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 25973332 Free PMC article. Review.
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck SAJ, Mathijssen RHJ, Jaehde U, Gillessen S, Joerger M. Omlin A, et al. Among authors: loidl w. Clin Cancer Res. 2023 May 15;29(10):1887-1893. doi: 10.1158/1078-0432.CCR-22-3360. Clin Cancer Res. 2023. PMID: 36917691 Clinical Trial.
[Importance of genetic testing in prostate cancer].
Steinkellner L, Luger F, Loidl W. Steinkellner L, et al. Among authors: loidl w. Urologie. 2022 Dec;61(12):1392-1398. doi: 10.1007/s00120-022-01977-3. Epub 2022 Nov 15. Urologie. 2022. PMID: 36378280 German.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, McComb M, Wittemer-Rump S, Koca G, Stienen S, Bargou RC, Hummel HD, Loidl W, Grüllich C, Eggert T, Tran B, Mytych DT. Penny HL, et al. Among authors: loidl w. Front Immunol. 2023 Oct 23;14:1261070. doi: 10.3389/fimmu.2023.1261070. eCollection 2023. Front Immunol. 2023. PMID: 37942314 Free PMC article.
67 results